Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 4/20 | 0.38 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12753924 | 1.00 | PTGS2 (0.38) | PTGS2PTGS1TDP1 | |
| SCHEMBL12753926 | 1.00 | PTGS2 (0.38) | PTGS2PTGS1TDP1 | |
| SCHEMBL12753882 | 0.85 | ALDH1A1 (0.31) | — | |
| SCHEMBL12753945 | 0.84 | PTGS2 (0.40) | PTGS2PTGS1 | |
| SCHEMBL12753944 | 0.84 | PTGS2 (0.40) | PTGS2PTGS1 | |
| SCHEMBL12374857 | 0.84 | PTGS2 (0.40) | PTGS2PTGS1 | |
| SCHEMBL9325278 | 0.82 | PTGS2 (0.35) | PTGS2PTGS1 | |
| SCHEMBL12374859 | 0.82 | PTGS2 (0.38) | PTGS2PTGS1 | |
| SCHEMBL23421023 | 0.81 | PTGS1 (0.36) | PTGS2PTGS1 | |
| SCHEMBL20100773 | 0.80 | HPGD (0.38) | PTGS2PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8003811-B2 | Nitric oxide donor compounds | NICOX S.A. (FR) | 2011-08-23 | — | — | US | disclosed |
| US-20110077279-A1 | ANGIOTENSIN II RECEPTOR ANTAGONISTS | NICOX S.A. (FR) | 2011-03-31 | — | — | US | disclosed |
| US-20100249189-A1 | NITRIC OXIDE DONOR COMPOUNDS | NICOX S.A. (FR) | 2010-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110077279-A1 | ANGIOTENSIN II RECEPTOR ANTAGONISTS | AGTR1, AGTR2, AGT | PTGS2 428/4885PTGS1 656/4885TDP1 4673/4885 |
| US-20100249189-A1 | NITRIC OXIDE DONOR COMPOUNDS | NOS3, NOS1, NOS2 | PTGS2 105/4885PTGS1 56/4885TDP1 1673/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.